Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

NCT04589728 · clinicaltrials.gov ↗

COMPLETED

Status

202

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Venetoclax plus HMA

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto